Search the Newsreel

Vertex Pharmaceuticals: Bereinigter Gewinn und Umsatz im 2. Quartal steigen; Prognose für 2026 angehoben

Vertex Lifted Its Revenue Outlook As Alyftrek Picked Up Steam

Vertex Pharmaceuticals increased its full-year revenue forecast to $13.1-13.2 billion, driven by strong performance from its new cystic fibrosis drug, Alyftrek. The company's second-quarter revenue reached $3.33 billion, exceeding analyst estimates, with Alyftrek contributing significantly. A new, higher forecast is anticipated after the completion …

Vertex Pharmaceuticals Incorporated erhöht Gewinnprognose für das Gesamtjahr 2026

Vertex Pharma beats Q2 earnings and revenue estimates, raises guidance

Vertex Pharmaceuticals reported Q2 adjusted EPS of $4.73 and revenue of $3.33 billion, both exceeding analyst expectations. The company also raised its full-year 2026 revenue guidance to $13.1 billion to $13.2 billion, driven by strong performance in cystic fibrosis therapies and growth in non-CF …

Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

Vertex Pharmaceuticals Inc. (VRTX) stock decreased by 1.34% to $470.72 on Monday, marking its fourth consecutive day of losses. Despite this decline, the stock still outperformed the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average both rise.

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For

Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals beat analysts' revenue expectations last quarter, reporting revenues of $2.99 billion, up …

Vertex Pharmaceuticals hebt Jahresprognose nach starkem Q2-Umsatzwachs

Informe de resultados: Vertex supera estimaciones del Q2 2026 y eleva previsiones de ingresos

VRTX|Vertex Pharmaceuticals Inc|Kurs:496.070|Änderung %:+12.040

AbCellera Biologics (ABCL) Signs Vertex Deal, Is The Stock Still Cheap?

AbCellera Biologics (ABCL) has signed a new collaboration with Vertex Pharmaceuticals for autoimmune disease treatments. Despite a recent share price rebound, the stock remains undervalued according to Simply Wall St's narrative, suggesting a fair value of $10.43 compared to its last close of $5.71. …

Vertex Pharmaceuticals Stock (VRTX) Opinions on Upcoming Earnings

This article summarizes social media discussions and financial data regarding Vertex Pharmaceuticals (VRTX) ahead of its upcoming earnings report. Investors are focused on cystic fibrosis treatment updates and pipeline progress, alongside VRTX's competitive position in gene therapies. The report also details recent insider trading, …

RYTM|Rhythm Pharmaceuticals Inc|Price:105.800|Chg%:-0.730

Rhythm Pharmaceuticals Inc (RYTM) has strong fundamentals, high growth potential, and is considered fairly valued within the pharmaceuticals industry. Institutional ownership is high, and analysts largely rate it as a "Buy" with an expected upward trend in the medium term. The company specializes in …

Die Allianz zwischen Vertex und AbCellera im Bereich T-Zell-Engager könnte die Argumente für eine Investition in Vertex Pharmaceuticals (VRTX) verändern

Vertex–AbCellera T‑Cell Engager Alliance Might Change The Case For Investing In Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals has announced a collaboration with AbCellera Biologics to develop multispecific T-cell engagers for autoimmune diseases, broadening Vertex's pipeline beyond its core genetic medicine strengths. This alliance, alongside the recent FDA expansion for CASGEVY, diversifies Vertex's investment narrative, although concerns about CF concentration …

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

The biopharmaceutical industry has seen active mergers and acquisitions, highlighted by Vertex Pharmaceuticals' $10 billion acquisition of Crinetics Pharmaceuticals. This article suggests that Viking Therapeutics, with its promising weight loss drug pipeline including VK2735 currently in Phase 3 trials, could be the next major …

Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress

Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk …

SNOA|Sonoma Pharmaceuticals Inc|Price:1.100|Chg%:-0.040

Sonoma Pharmaceuticals Inc. (SNOA) shows strong fundamentals with high growth potential, averaging 53.35% revenue growth over three years. Despite recent stock market underperformance, its valuation is considered fairly valued within the Pharmaceuticals industry. The company, which develops and produces stabilized hypochlorous acid (HOCl) products …

TNXP|Tonix Pharmaceuticals Holding Corp|Price:9.510|Chg%:-0.430

This article provides a comprehensive stock analysis of Tonix Pharmaceuticals Holding Corp (TNXP) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and current valuation as "fairly valued" within the pharmaceuticals industry. The report also notes high institutional ownership, positive analyst ratings …

AbCellera, Vertex Partner on Multispecific T-Cell Engagers for Autoimmune Disease

AbCellera and Vertex Pharmaceuticals have announced a collaboration to develop multispecific T-cell engagers for autoimmune diseases, coinciding with Roche's withdrawal of its lupus T-cell engager program due to clinical data. This strategic move allows Vertex to expand into high-unmet-need autoimmune conditions, leveraging AbCellera's antibody …

Is Vertex Pharmaceuticals (VRTX) Cheap On Its AbCellera Collaboration News?

Vertex Pharmaceuticals (VRTX) has garnered attention due to a new collaboration with AbCellera Biologics to develop multispecific T cell engagers for autoimmune diseases. Despite a 13.09% return in the last 90 days, the stock is currently trading at a discount to intrinsic estimates and …

Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 1.44% on Wednesday, closing at $483.33. This underperformance occurred on a generally negative trading day, with both the S&P 500 Index and the Dow Jones Industrial Average also declining. The stock's drop ended a four-day winning streak.

Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Vertex Pharmaceuticals has delivered a 145.1% return over the past five years, yet its current valuation picture is mixed, as a Discounted Cash …

AbCellera, Vertex partner on next-gen T-cell engagers

Vertex Pharmaceuticals has partnered with AbCellera to develop novel T-cell engagers for autoimmune diseases, with AbCellera receiving $28 million upfront and potential milestone payments. This collaboration expands Vertex's efforts to diversify beyond its successful cystic fibrosis business and capitalize on the growing interest in …

Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX) will report quarterly earnings of $4.85 per share in its upcoming release, pointing to a year-over-year increase of 7.3%. It is anticipated that revenues will amount to $3.23 billion, exhibiting an increase of 8.8% compared to …

Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera

Vertex Pharmaceuticals has paid AbCellera $28 million upfront for a collaboration to develop T-cell engagers (TCEs) for autoimmune conditions. AbCellera will handle discovery and early development, with Vertex funding R&D and securing rights to resulting TCEs, plus agreeing to potential milestone payments and royalties. …

AbCellera partners with Vertex on autoimmune therapies

AbCellera Biologics Inc. announced a collaboration with Vertex Pharmaceuticals Incorporated to develop multispecific T-cell engagers for autoimmune diseases. AbCellera will lead discovery and early development, receiving $28 million upfront plus potential milestone payments and royalties, while Vertex funds all R&D and retains commercialization rights. …

ANIP|ANI Pharmaceuticals Inc|Price:79.255|Chg%:-1.175

This article provides a comprehensive stock analysis of ANI Pharmaceuticals Inc (ANIP) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The analysis also covers institutional ownership, analyst ratings, and a detailed breakdown of how …

Vertex (VRTX) Stock May Sit Below Fair Value On Cash Flow

Vertex Pharmaceuticals (VRTX) stock shows mixed signals, with a Discounted Cash Flow (DCF) analysis suggesting it is 31.4% undervalued, while its P/E ratio is close to fair value. The company's 5-year return is strong at 145.1%, but its 1-year return lags peers. The article …

Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider

Vertex Pharmaceuticals (VRTX) recently outperformed the S&P 500, closing up +2.38%. The company is set to report earnings on August 3, 2026, with analysts forecasting a 7.3% EPS increase and 8.78% revenue growth year-over-year. Despite a recent drop in the Zacks Consensus EPS estimate, …

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have …

Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?

Vertex Pharmaceuticals VRTX is scheduled to report its second-quarter 2026 results on Aug. 3, after market close. The Zacks Consensus Estimate for the to-be-reported quarter's revenues is pegged at $3.23 billion, while the same for earnings is $4.85 per share. Let's see how things …

XFOR|X4 Pharmaceuticals Inc|Price:4.000|Chg%:+0.070

TradingKey provides a comprehensive stock analysis for X4 Pharmaceuticals Inc (XFOR), highlighting its strong fundamentals, high growth potential, and relatively fair valuation. The company is in a growing phase with a lead clinical candidate, mavorixafor, and has received a "Strong Buy" rating from analysts …

ALNY|Alnylam Pharmaceuticals Inc|Price:287.630|Chg%:-0.780

This article provides a comprehensive stock analysis of Alnylam Pharmaceuticals Inc (ALNY), highlighting its strong fundamentals, high growth potential, and "fairly valued" status. It notes that institutional ownership is high and analysts largely rate it as a "Buy" with a target price of $440.59. …

RIGL|Rigel Pharmaceuticals Inc|Price:37.126|Chg%:-0.264

This article provides a comprehensive stock analysis of Rigel Pharmaceuticals Inc (RIGL) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways recently. The analysis also covers the company's valuation, institutional ownership, and analyst ratings, indicating a …

Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Madrigal Pharmaceuticals Inc (MDGL), outlining both major shareholders and institutional holdings. Key shareholders include Baker Bros. Advisors LP, RTW Investments L.P., and Avoro Capital Advisors LLC. The analysis also provides statistics on the types of shareholders, institutional …

PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005

Processa Pharmaceuticals Inc. (PCSA) is a clinical-stage biopharmaceutical company focused on Next Generation Cancer therapy (NGC) small molecules. The company's stock is currently trading at $2.565, with recent positive performance over the last month and a high institutional ownership. While fundamentals are strong and …